Product Pipeline for New Pharmaceutical Drugs
OUR MEDICINES IN DEVELOPMENT
Our priority is researching and developing medicines and vaccines that will benefit patients around the world. We are committed to addressing unmet needs across a number of important therapeutic areas including, Oncology, Inflammation & Immunology, Vaccines, Internal Medicine and Rare Disease, with the goal of delivering innovative products to patients.
Pipeline Snapshot as of July 28, 2021
- Discovery Projects
- 29Phase 1
- 40Phase 2
- 23Phase 3
- 8Registration
- Total100
| Compound Name | Indication | Phase | Submission Type | Compound Type |
|---|---|---|---|---|
Lorbrena (lorlatinib) Therapeutic Area: Oncology Phase:Registration Compound Type:Small Molecule Business Segment: Biopharma Mechanism of Action: ALK inhibitor | 1st Line ALK Non-Small Cell Lung Cancer (E.U.) | Registration | Product Enhancement | Small Molecule |
Braftovi (encorafinib) + Mektovi (binimetinib) Therapeutic Area: Oncology Phase:Phase 2 Compound Type:Small Molecule Business Segment: Biopharma Mechanism of Action: BRAF kinase inhibitor andMEK inhibitor | 1st line and 2nd line BRAF-mutant Metastatic Non-Small Cell Lung Cancer | Phase 2 | Product Enhancement | Small Molecule |
Braftovi (encorafinib) + Erbitux® (cetuximab) Therapeutic Area: Oncology Phase:Phase 3 Compound Type:Small Molecule Business Segment: Biopharma Mechanism of Action: BRAF kinase inhibitor and anti EGFR | 1st line BRAF-mutant Metastatic Colorectal Cancer | Phase 3 | Product Enhancement | Small Molecule |
Bavencio (avelumab) Therapeutic Area: Oncology Phase:Phase 3 Compound Type:Biologic Business Segment: Biopharma Mechanism of Action: Anti PD-L1 | 1st Line Non-Small Cell Lung Cancer (Biologic) | Phase 3 | Product Enhancement | Biologic |
Talzenna (talazoparib) Therapeutic Area: Oncology Phase:Phase 2 Compound Type:Small Molecule Business Segment: Biopharma Mechanism of Action: PARP inhibitor | 2nd Line Metastatic Castration-Resistant Prostate Cancer | Phase 2 | Product Enhancement | Small Molecule |
recifercept Therapeutic Area: Rare Diseases Phase:Phase 2 Compound Type:Biologic Business Segment: WRDM Mechanism of Action: Soluble recombinant human fibroblast growth factor receptor 3 (FGFR3) decoy | Achondroplasia (Biologic) (ORPHAN - U.S.) | Phase 2 | New Molecular Entity | Biologic |
somatrogon (PF-06836922) Therapeutic Area: Rare Diseases Phase:Phase 3 Compound Type:Biologic Business Segment: Biopharma Mechanism of Action: Human Growth Hormone Agonist | Adult Growth Hormone Deficiency (Biologic) (ORPHAN - U.S., E.U.) | Phase 3 | Product Enhancement | Biologic |
brepocitinib (PF-06700841) Therapeutic Area: Inflammation & Immunology Phase:Phase 2 Compound Type:Small Molecule Business Segment: WRDM Mechanism of Action: TYK2/JAK1 Inhibitor | Alopecia Areata | Phase 2 | Product Enhancement | Small Molecule |
ritlecitinib (PF-06651600) Therapeutic Area: Inflammation & Immunology Phase:Phase 3 Compound Type:Small Molecule Business Segment: Biopharma Mechanism of Action: JAK3/TEC Inhibitor | Alopecia Areata (BREAKTHROUGH) | Phase 3 | New Molecular Entity | Small Molecule |
Xeljanz (tofacitinib) Therapeutic Area: Inflammation & Immunology Phase:Registration Compound Type:Small Molecule Business Segment: Biopharma Mechanism of Action: JAK Inhibitor | Ankylosing Spondylitis (U.S., E.U.) | Registration | Product Enhancement | Small Molecule |
PF-07258669 Therapeutic Area: Internal Medicine Phase:Phase 1 Compound Type:Small Molecule Business Segment: WRDM Mechanism of Action: Melanocortin-4 receptor (MC4R) Antagonist | Anorexia | Phase 1 | New Molecular Entity | Small Molecule |
brepocitinib (PF-06700841) Therapeutic Area: Inflammation & Immunology Phase:Phase 2 Compound Type:Small Molecule Business Segment: WRDM Mechanism of Action: Topical TYK2/JAK1 Inhibitor | Atopic Dermatitis | Phase 2 | New Molecular Entity | Small Molecule |
PF-07038124 Therapeutic Area: Inflammation & Immunology Phase:Phase 2 Compound Type:Small Molecule Business Segment: WRDM Mechanism of Action: Topical PDE4 Inhibitor | Atopic Dermatitis | Phase 2 | New Molecular Entity | Small Molecule |
PF-07242813 Therapeutic Area: Inflammation & Immunology Phase:Phase 1 Compound Type:Biologic Business Segment: WRDM Mechanism of Action: CD1a inhibitor | Atopic Dermatitis (Biologic) | Phase 1 | New Molecular Entity | Biologic |
abrocitinib (PF-04965842) Therapeutic Area: Inflammation & Immunology Phase:Registration Compound Type:Small Molecule Business Segment: Biopharma Mechanism of Action: JAK1 Inhibitor | Atopic Dermatitis (PRIORITY REVIEW, BREAKTHROUGH - U.S., E.U.) | Registration | New Molecular Entity | Small Molecule |
Braftovi (encorafinib) + Mektovi (binimetinib) + Keytruda®(pembrolizumab) Therapeutic Area: Oncology Phase:Phase 3 Compound Type:Small Molecule Business Segment: Biopharma Mechanism of Action: BRAF kinase inhibitor andMEK inhibitor and anti PD-1 | BRAF-mutant Metastatic or Unresectable Locally Advanced Melanoma | Phase 3 | Product Enhancement | Small Molecule |
PF-06873600 Therapeutic Area: Oncology Phase:Phase 1 Compound Type:Small Molecule Business Segment: WRDM Mechanism of Action: CDK 2,4,6 Inhibitor | Breast Cancer Metastatic | Phase 1 | New Molecular Entity | Small Molecule |
PF-07104091 Therapeutic Area: Oncology Phase:Phase 1 Compound Type:Small Molecule Business Segment: WRDM Mechanism of Action: CDK2 Inhibitor | Breast Cancer Metastatic | Phase 1 | New Molecular Entity | Small Molecule |
